ArticleMuscle & nerve2026
IgG Subclass (IgG1-4) and IgA Autoantibody Profiles Against Muscle-Specific Kinase in a Greek Cohort.
Article in Muscle & nerve, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IgG Subclass (IgG1-4) and IgA Autoantibody Profiles Against Muscle-Specific Kinase in a Greek Cohort.Muscle & nerve · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
INTRODUCTION/
aimsMuscle-specific kinase myasthenia gravis (MuSK-MG) is an autoimmune neuromuscular disorder predominantly mediated by IgG4 autoantibodies disrupting MuSK signaling. The contribution of other isotypes remains incompletely defined. We characterized the serological profile of a Greek cohort of MuSK-MG patients.
methodsBaseline (n = 140) and longitudinal (available n = 99) samples from 140 patients, positive for anti-MuSK by radioimmunoprecipitation (RIPA) were analyzed using a live cell-based assay (L-CBA) to detect total IgG, IgG1-4 subclasses, IgM, and IgA. Also, disease and healthy controls (n = 102) were included. Selected samples were additionally analyzed by flow cytometry. Clinical data were available for specific patients.
resultsOur analysis revealed 15 distinct immunoglobulin combinations and provided insights into the presence of IgA isotype. IgG4 was the most common subclass in 120/140 of patients, followed by IgG1 in 79/140, IgG3 in 59/140, and IgG2 in 42/140 patients, while IgM positivity was detected in selected patients. Anti-MuSK IgA(1) immunoreactivity was detected in 54/140 patients, frequently co-occurring with IgG, and in four patients at baseline with only-IgA positivity. IgA was detected both near disease onset and at later stages, and persisted over time in rituximab-treated patients. Controls tested largely negative for IgA, although low-intensity signals were observed in six samples and were considered non-specific. L-CBA detected anti-MuSK IgA more frequently than flow cytometry. DISCUSSION: Our findings expand the serology of MuSK-MG beyond IgG subclasses, identifying IgA as an additional component of the anti-MuSK response. These results enhance further investigation into the clinical significance, pathogenic potential, and treatment-associated fluctuations of anti-MuSK IgA antibodies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.